MedPath

Research Ethics Board Approves Amendment to Canadian COVID-19 Treatment Trial to Include LSALT Peptide

The Research Ethics Board at Sunnybrook Research Institute has approved an amendment to the CATCO trial protocol to include LSALT Peptide, a drug candidate by Arch Biopartners Inc., for treating organ damage caused by inflammation, in a new arm of the trial. The next step is seeking Health Canada's approval before dosing begins.

Arch Biopartners Inc., a clinical stage company focused on developing new drug candidates for treating organ damage caused by inflammation, announced that the Research Ethics Board at the Sunnybrook Research Institute has approved an amendment to the CATCO protocol. This amendment includes the company's lead drug candidate, LSALT Peptide (also known as Metablok), in a new arm of the CATCO human trial.
The CATCO leadership is now set to seek Health Canada approval before commencing the dosing of LSALT in the new arm of the trial. This development marks a significant step forward in the research and potential treatment options for COVID-19 related organ damage, leveraging the anti-inflammatory properties of LSALT Peptide.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Arch Biopartners Advances AKI Programs: LSALT Peptide and Cilastatin Trials Progress

Arch Biopartners' Phase II trial of LSALT peptide for cardiac surgery-associated acute kidney injury (CS-AKI) gains ethics approval in Ontario, with patient recruitment set to begin in Toronto.
A 700-patient Phase II trial (PONTiAK) evaluating cilastatin for preventing drug-induced AKI receives a No Objection Letter from Health Canada, paving the way for the trial to proceed.

Abbott India Granted Approval for Phase III Clinical Trial of Ursodeoxycholic Acid Tablet

Abbott India has received approval from the CDSCO's Subject Expert Committee to conduct a Phase III clinical trial for Ursodeoxycholic Acid tablets, aimed at treating primary biliary cirrhosis. The approval follows the submission of a revised trial protocol addressing specific committee recommendations.

Arch Biopartners Doses First Patient in Canada for Phase II Trial of LSALT Peptide in Cardiac Surgery-Associated Acute Kidney Injury

Arch Biopartners has initiated patient recruitment and dosing in Canada for its Phase II trial of LSALT peptide, targeting cardiac surgery-associated acute kidney injury (CS-AKI).
The trial is a multi-center, randomized, double-blind, placebo-controlled study aiming to enroll 240 patients across sites in Canada and Turkey.

Arch Biopartners Initiates Phase II Trial of LSALT Peptide for Cardiac Surgery-Associated Acute Kidney Injury

Arch Biopartners has commenced a Phase II clinical trial of LSALT peptide for preventing and treating cardiac surgery-associated acute kidney injury (CS-AKI).
The trial is a multicenter, randomized, double-blind, placebo-controlled study aiming to enroll 240 patients undergoing on-pump cardiac surgery.

Arch Biopartners Doses First Patient in Phase II Trial for Cardiac Surgery-Associated Acute Kidney Injury

Arch Biopartners has dosed the first patient in Canada for its Phase II trial evaluating LSALT peptide for preventing cardiac surgery-associated acute kidney injury (CS-AKI).
The multi-center, randomized, double-blind, placebo-controlled study aims to enroll 240 patients to assess LSALT peptide's efficacy in reducing AKI incidence within seven days post-surgery.

Arch Biopartners Doses First Patient in Phase II Trial of LSALT Peptide for Cardiac Surgery-Associated Acute Kidney Injury

Arch Biopartners has initiated patient dosing in Canada for its Phase II trial of LSALT peptide, targeting cardiac surgery-associated acute kidney injury (CS-AKI).
The multi-center, randomized, double-blind, placebo-controlled study aims to enroll 240 patients internationally to assess LSALT peptide's efficacy in preventing AKI.

Arch Biopartners Initiates Phase II Trial of LSALT Peptide for Cardiac Surgery-Associated Acute Kidney Injury

Arch Biopartners has dosed the first patient in Canada for its Phase II trial of LSALT peptide, targeting cardiac surgery-associated acute kidney injury (CS-AKI).
The multi-center, randomized, double-blind, placebo-controlled study aims to enroll 240 patients to evaluate LSALT peptide's efficacy in preventing AKI post-cardiac surgery.

Arch Biopartners' LSALT Peptide Phase II Trial Approved for Cardiac Surgery-Associated Acute Kidney Injury

Arch Biopartners has received approval from Alberta Health Services for a Phase II trial of LSALT peptide in cardiac surgery-associated acute kidney injury (CS-AKI).
The trial is a multi-center, randomized, double-blind, placebo-controlled study with a target recruitment of 240 patients across multiple sites.

Arch Biopartners Receives Ethics Approval for Phase II Trial of LSALT Peptide in Calgary

Arch Biopartners Inc. has announced that the University of Calgary’s Conjoint Health Research Ethics Board has approved a Phase II trial for LSALT peptide, aimed at preventing and treating cardiac surgery-associated acute kidney injury (CS-AKI). The trial, which is also recruiting patients in Turkey, seeks to evaluate the effectiveness of LSALT peptide in reducing AKI incidents post-cardiac surgery.

Arch Biopartners' LSALT Peptide Phase II Trial for Cardiac Surgery-Associated Acute Kidney Injury Approved in Turkey

Arch Biopartners received ethics approval in Turkey for a Phase II trial of LSALT peptide, aimed at preventing and treating cardiac surgery-associated acute kidney injury (CS-AKI).
The trial will assess LSALT peptide's efficacy in reducing inflammation injury in kidneys, lungs, and liver by targeting the dipeptidase-1 (DPEP-1) pathway.

Reference News

[1]
Research Ethics Board approves amendment to Canadian ...
theglobeandmail.com · Jan 4, 2022

Arch Biopartners Inc. announced the Research Ethics Board at Sunnybrook Research Institute approved an amendment to incl...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy